| Comprehensive molecular profiling of lung adenocarcinoma Cancer Genome Atlas Research Network Nature 511 (7511), 543, 2014 | 4030* | 2014 |
| STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung AdenocarcinomaSTK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant LUAC F Skoulidis, ME Goldberg, DM Greenawalt, MD Hellmann, MM Awad, ... Cancer discovery 8 (7), 822-835, 2018 | 992 | 2018 |
| The BATTLE trial: personalizing therapy for lung cancer ES Kim, RS Herbst, II Wistuba, JJ Lee, GR Blumenschein Jr, A Tsao, ... Cancer discovery 1 (1), 44-53, 2011 | 960 | 2011 |
| Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing J Zhang, J Fujimoto, J Zhang, DC Wedge, X Song, J Zhang, S Seth, ... Science 346 (6206), 256-259, 2014 | 936 | 2014 |
| An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor … LA Byers, L Diao, J Wang, P Saintigny, L Girard, M Peyton, L Shen, Y Fan, ... Clinical cancer research 19 (1), 279-290, 2013 | 924 | 2013 |
| Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic … DR Gomez, GR Blumenschein, JJ Lee, M Hernandez, R Ye, DR Camidge, ... The lancet oncology 17 (12), 1672-1682, 2016 | 854 | 2016 |
| Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression L Chen, DL Gibbons, S Goswami, MA Cortez, YH Ahn, LA Byers, X Zhang, ... Nature communications 5 (1), 5241, 2014 | 802 | 2014 |
| PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib JA Engelman, K Zejnullahu, CM Gale, E Lifshits, AJ Gonzales, ... Cancer research 67 (24), 11924-11932, 2007 | 781 | 2007 |
| Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional … DR Gomez, C Tang, J Zhang, GR Blumenschein Jr, M Hernandez, JJ Lee, ... Journal of Clinical Oncology 37 (18), 1558, 2019 | 780 | 2019 |
| Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic VulnerabilitiesCo-occurring … F Skoulidis, LA Byers, L Diao, VA Papadimitrakopoulou, P Tong, J Izzo, ... Cancer discovery 5 (8), 860-877, 2015 | 654 | 2015 |
| Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data CM Rudin, JT Poirier, LA Byers, C Dive, A Dowlati, J George, JV Heymach, ... Nature Reviews Cancer 19 (5), 289-297, 2019 | 601 | 2019 |
| Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with … S Kopetz, PM Hoff, JS Morris, RA Wolff, C Eng, KY Glover, R Adinin, ... Journal of clinical oncology 28 (3), 453, 2010 | 521 | 2010 |
| Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer JA Engelman, T Mukohara, K Zejnullahu, E Lifshits, AM Borrás, CM Gale, ... The Journal of clinical investigation 116 (10), 2695-2706, 2006 | 516 | 2006 |
| Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome NT Ihle, LA Byers, ES Kim, P Saintigny, JJ Lee, GR Blumenschein, A Tsao, ... Journal of the National Cancer Institute 104 (3), 228-239, 2012 | 504 | 2012 |
| Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial RS Herbst, Y Sun, WEE Eberhardt, P Germonpré, N Saijo, C Zhou, ... The lancet oncology 11 (7), 619-626, 2010 | 489 | 2010 |
| A pan-cancer proteomic perspective on The Cancer Genome Atlas R Akbani, PKS Ng, HMJ Werner, M Shahmoradgoli, F Zhang, Z Ju, W Liu, ... Nature communications 5 (1), 3887, 2014 | 485 | 2014 |
| Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung CancerDDR Inhibition Enhances Antitumor Immunity in SCLC T Sen, BL Rodriguez, L Chen, CMD Corte, N Morikawa, J Fujimoto, ... Cancer discovery 9 (5), 646-661, 2019 | 480 | 2019 |
| Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy F Skoulidis, JV Heymach Nature Reviews Cancer 19 (9), 495-509, 2019 | 472 | 2019 |
| Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1 LA Byers, J Wang, MB Nilsson, J Fujimoto, P Saintigny, J Yordy, U Giri, ... Cancer discovery 2 (9), 798-811, 2012 | 466 | 2012 |
| Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non–small-cell lung cancer JW Welsh, R Komaki, A Amini, MF Munsell, W Unger, PK Allen, JY Chang, ... Journal of Clinical Oncology 31 (7), 895, 2013 | 463 | 2013 |
Don L. Gibbons, MD, PhDProfessor, Dept. of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer CenterVerified email at mdanderson.org
